Search research articles
Contact Us
Filters
Showing results (51-60 of 72) with videos related to
Page
of 8
Sort By:
Breast Cancer Research and Treatment
|
August 11, 2018
Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer
Adrienne E Borrie, Rhiannon V Rose, Yun-Hee Choi, et al.
JAMA Network Open
|
January 11, 2020
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
Xavier Paoletti, Liz-Anne Lewsley, Gennaro Daniele, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2018
A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium
Stephanie Lheureux, Anna Tinker, Blaise Clarke, et al.
Cancer Medicine
|
November 15, 2019
Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis
Kelvin K W Chan, Helen Guo, Sierra Cheng, et al.
Journal of Gastrointestinal Oncology
|
January 13, 2023
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma
Kyaw L Aung, Elaine McWhirter, Stephen Welch, et al.
The Journal of Molecular Diagnostics : JMD
|
February 7, 2026
Health care impact of comprehensive genomic profiling of solid tumors in patient management using POWER (Precision Oncology at Western University)
Pratibha Bhai, Jacob P Turowec, Lee-Anne Pickard, et al.
Gynecologic Oncology
|
October 4, 2021
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
Elizabeth M Swisher, Rebecca S Kristeleit, Amit M Oza, et al.
Nature Communications
|
August 26, 2022
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
Daniel J Renouf, Jonathan M Loree, Jennifer J Knox, et al.
Nature Communications
|
March 7, 2026
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma
Daniel J Renouf, James T Topham, Jonathan M Loree, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2020
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Neesha C Dhani, Hal W Hirte, Lisa Wang, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 72) with videos related to
Sort By:
Page
of 8
Breast Cancer Research and Treatment
|
August 11, 2018
Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer
Adrienne E Borrie, Rhiannon V Rose, Yun-Hee Choi, et al.
JAMA Network Open
|
January 11, 2020
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
Xavier Paoletti, Liz-Anne Lewsley, Gennaro Daniele, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2018
A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium
Stephanie Lheureux, Anna Tinker, Blaise Clarke, et al.
Cancer Medicine
|
November 15, 2019
Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis
Kelvin K W Chan, Helen Guo, Sierra Cheng, et al.
Journal of Gastrointestinal Oncology
|
January 13, 2023
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma
Kyaw L Aung, Elaine McWhirter, Stephen Welch, et al.
The Journal of Molecular Diagnostics : JMD
|
February 7, 2026
Health care impact of comprehensive genomic profiling of solid tumors in patient management using POWER (Precision Oncology at Western University)
Pratibha Bhai, Jacob P Turowec, Lee-Anne Pickard, et al.
Gynecologic Oncology
|
October 4, 2021
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
Elizabeth M Swisher, Rebecca S Kristeleit, Amit M Oza, et al.
Nature Communications
|
August 26, 2022
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
Daniel J Renouf, Jonathan M Loree, Jennifer J Knox, et al.
Nature Communications
|
March 7, 2026
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma
Daniel J Renouf, James T Topham, Jonathan M Loree, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2020
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Neesha C Dhani, Hal W Hirte, Lisa Wang, et al.
Page
of 8